Regeneron Pharmaceuticals Inc
REGN749.790USD
+3.430+0.46%
Handelsschluss 12/17, 16:00（ET）Kurse um 15 Minuten verzögert
78.95BMarktkapitalisierung
17.29KGV TTM
mehr Informationen über Regeneron Pharmaceuticals Inc Unternehmen
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Inc Informationen
BörsenkürzelREGN
Name des UnternehmensRegeneron Pharmaceuticals Inc
IPO-datumApr 02, 1991
CEOSchleifer (Leonard S)
Anzahl der mitarbeiter15106
WertpapierartOrdinary Share
GeschäftsjahresendeApr 02
Addresse777 Old Saw Mill River Road
StadtTARRYTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10591
Telefon17813705000
Websitehttps://www.regeneron.com/
BörsenkürzelREGN
IPO-datumApr 02, 1991
CEOSchleifer (Leonard S)
Führungskräfte von Regeneron Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.78K
+10.31%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
15.51K
+7.93%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Andere
421.70M
11.47%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Andere
421.70M
11.47%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
Andere
74.20%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
Andere
74.20%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
45.11%
Investment Advisor/Hedge Fund
30.91%
Hedge Fund
5.04%
Pension Fund
2.69%
Research Firm
2.61%
Bank and Trust
2.25%
Individual Investor
2.06%
Sovereign Wealth Fund
1.23%
Insurance Company
0.20%
Andere
7.90%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
2596
94.26M
91.26%
-4.21M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
9.37M
9%
+14.55K
+0.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.67M
5.44%
-75.61K
-1.32%
Jun 30, 2025
State Street Investment Management (US)
4.83M
4.64%
+42.34K
+0.88%
Jun 30, 2025
Dodge & Cox
3.83M
3.67%
+1.50M
+64.64%
Jun 30, 2025
JP Morgan Asset Management
2.82M
2.7%
-1.26M
-30.95%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.47M
2.37%
-4.53K
-0.18%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
2.17M
2.09%
-7.70K
-0.35%
Aug 31, 2025
Putnam Investment Management, L.L.C.
2.03M
1.95%
+116.30K
+6.08%
Jun 30, 2025
Capital World Investors
1.97M
1.89%
+27.38K
+1.41%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
1.94M
1.86%
+305.09K
+18.65%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
6.6%
Invesco Nasdaq Biotechnology ETF
6.55%
Amplify Weight Loss Drug & Treatment ETF
6.4%
iShares Biotechnology ETF
5.9%
Simplify Health Care ETF
5.54%
VanEck Biotech ETF
5.51%
Invesco Biotechnology & Genome ETF
5.4%
iShares Genomics Immunology and Healthcare ETF
4.97%
First Trust NASDAQ Pharmaceuticals ETF
4.36%
First Trust NYSE Arca Biotechnology Index Fund
3.88%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil6.6%
Invesco Nasdaq Biotechnology ETF
Anteil6.55%
Amplify Weight Loss Drug & Treatment ETF
Anteil6.4%
iShares Biotechnology ETF
Anteil5.9%
Simplify Health Care ETF
Anteil5.54%
VanEck Biotech ETF
Anteil5.51%
Invesco Biotechnology & Genome ETF
Anteil5.4%
iShares Genomics Immunology and Healthcare ETF
Anteil4.97%
First Trust NASDAQ Pharmaceuticals ETF
Anteil4.36%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.88%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Regeneron Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Regeneron Pharmaceuticals Inc sind:
The Vanguard Group, Inc. hält 9.37M Aktien, was 9.00% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 5.67M Aktien, was 5.44% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 4.83M Aktien, was 4.64% der Gesamtaktien entspricht.
Dodge & Cox hält 3.83M Aktien, was 3.67% der Gesamtaktien entspricht.
JP Morgan Asset Management hält 2.82M Aktien, was 2.70% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 9.37M Aktien, was 9.00% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 5.67M Aktien, was 5.44% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 4.83M Aktien, was 4.64% der Gesamtaktien entspricht.
Dodge & Cox hält 3.83M Aktien, was 3.67% der Gesamtaktien entspricht.
JP Morgan Asset Management hält 2.82M Aktien, was 2.70% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Regeneron Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von Regeneron Pharmaceuticals Inc sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Regeneron Pharmaceuticals Inc (REGN)?
Mit Stand vom 2025Q3 halten 2596 Institutionen Anteile an Regeneron Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 94.26M, was 91.26% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -4.43% gestiegen.
Was ist die größte Einnahmequelle von Regeneron Pharmaceuticals Inc?
Am FY2025Q2 erzielte das Geschäft mit Sanofi für Regeneron Pharmaceuticals Inc den höchsten Umsatz in Höhe von 1.44B, was 39.28% des Gesamtumsatzes entspricht.
